Hiv-2 integrase variation in integrase inhibitor-naïve adults in senegal, west africa

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Gottlieb, Geoffrey S ^a   Smith, Robert A ^a   Badiane, Ndeye Mery ^b   Ba, Selly ^b   Hawes, Stephen E ^c   Toure, Macoumba ^b   Starling, Alison K ^a   Traore, Fatou ^b   Sall, Fatima ^b   Cherne, Stephen L ^a   Stern, Joshua ^a   Wong, Kim G ^a   Lu, Paul ^a   Kim, Moon ^a   Raugi, Dana N ^a   Lam, Airin ^a   Mullins, James I ^a   Kiviat, Nancy B ^a   Sow, Papa Salif ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Centre Hospitalier Universitaire Dakar   (Senegal)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; ENZYME POLYMORPHISM; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; SENEGAL; VIRUS RESISTANCE; DRUG EFFECT; ENZYMOLOGY; GENETICS; MIDDLE AGED; MOLECULAR GENETICS;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

ADULT; BASE SEQUENCE; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-2; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; SENEGAL; YOUNG ADULT;

EID: 79960219397     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022204     Document Type: Article

References (32)

1. De Cock KM, Adjorlolo G, Ekpini E, Sibailly T, Kouadio J, et al. (1993) Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic [published erratum appears in JAMA 1994 Jan 19;271(3):196] [see comments]. JAMA 3. 270: 2083-2086.
2. Simon F, Matheron S, Tamalet C, Loussert-Ajaka I, Bartczak S, et al. (1993) Cellular and plasma viral load in patients infected with HIV-2. AIDS 7: 1411-1417.
3. Marlink R, Kanki P, Thior I, Travers K, Eisen G, et al. (1994) Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265: 1587-1590.
4. Kanki PJ, Travers KU, MBoup S, Hsieh CC, Marlink RG, et al. (1994) Slower heterosexual spread of HIV-2 than HIV-1. Lancet 343: 943-946.
5. Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Redman M, et al. (2002) Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 185: 905-914.
6. Gottlieb GS, Hawes SE, Agne HD, Stern JE, Critchlow CW, et al. (2006) Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS 20: 895-900.
7. Hawes SE, Sow PS, Stern JE, Critchlow CW, Gottlieb GS, et al. (2008) Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding. AIDS 22: 2517-2525.
8. Matheron S, Pueyo S, Damond F, Simon F, Lepretre A, et al. (2003) Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort. Aids 17: 2593-2601.
9. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, et al. (2004) Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 9: 57-65.
10. Poveda E, Rodes B, Toro C, Soriano V, (2004) Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses 20: 347-348.
11. Smith RA, Gottlieb GS, Anderson DJ, Pyrak CL, Preston BD, (2008) Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob Agents Chemother 52: 329-332.
12. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, et al. (2008) In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors. Antimicrob Agents Chemother 52: 1545-1548.
13. Smith RA, Anderson DJ, Pyrak CL, Preston BD, Gottlieb GS, (2009) Antiretroviral Drug Resistance in HIV-2: Three Amino Acid Changes Are Sufficient for Classwide Nucleoside Analogue Resistance. J Infect Dis 199: 1323-1326.
14. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, et al. (2008) Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 82: 764-774.
15. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, et al. (2008) HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 62: 914-920.
16. Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, et al. (2010) In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS 24: 2753-2755.
17. Xu L, Anderson J, Ferns B, Cook P, Wildfire A, et al. (2008) Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients. AIDS Res Hum Retroviruses 24: 1003-1007.
18. Bercoff DP, Triqueneaux P, Lambert C, Oumar AA, Ternes AM, et al. (2010) Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology 7: 98.
19. Roquebert B, Blum L, Collin G, Damond F, Peytavin G, et al. (2008) Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS 22: 2045-2046.
20. Damond F, Lariven S, Roquebert B, Males S, Peytavin G, et al. (2008) Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 22: 665-666.
21. Salgado M, Toro C, Simon A, Garrido C, Blanco F, et al. (2009) Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J Clin Virol 46: 173-175.
22. Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, et al. (2008) Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS 22: 1091-1092.
23. Xu L, Anderson J, Garrett N, Ferns B, Wildfire A, et al. (2009) Dynamics of raltegravir resistance profile in an HIV type 2-infected patient. AIDS Res Hum Retroviruses 25: 843-847.
24. Armstrong-James D, Stebbing J, Scourfield A, Smit E, Ferns B, et al. (2010) Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res 86: 224-226.
25. Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, et al. (2011) Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir. Antimicrob Agents Chemother 55: 1293-1295.
26. Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, et al. (2009) Emergence of Multiclass Drug-Resistance in HIV-2 in Antiretroviral-Treated Individuals in Senegal: Implications for HIV-2 Treatment in Resource-Limited West Africa. Clin Infect Dis 48: 476-483.
27. Gottlieb GS, Hawes SE, Wong KG, Raugi DN, Agne HD, et al. (2008) HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal. AIDS Res Hum Retroviruses 24: 857-864.
28. Boyer PL, Sarafianos SG, Clark PK, Arnold E, Hughes SH, (2006) Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog 2: e10.
29. Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, et al. (2010) Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology 402: 338-346.
30. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, et al. (2011) In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 55: 813-821.
31. Gottlieb GS, Eholie SP, Nkengasong JN, Jallow S, Rowland-Jones S, et al. (2008) A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 22: 2069-2072; discussion 2073-2064.
32. Matheron S, (2008) HIV-2 infection: a call for controlled trials. AIDS 22 (16): 2073-2074.